Anti-CD4 MoAb therapy in kidney transplantation--a pilot study in early prophylaxis of rejection.

B-F5, a mouse IgG1 anti-CD4 MoAb, was used in recipients of a first cadaveric kidney allograft. Eighteen patients received 30 mg/day MoAb with a quadruple sequential therapy. All but one kidney were functioning at 6 months, with a mean serum creatinine of 153 micromol/L. However, 50% of the patients had an acute rejection episode within the first three months, and most of the early episodes (i.e., < 1 month) occurred in patients with low levels of circulating MoAb. The biological analysis showed a strong depleting effect on the CD4+ cell counts, a saturation by the MoAb of the remaining circulating CD4+ cells, and no detectable immunization against B-F5. Although the biological parameters indicate an action of B-F5 in vivo, the clinical data associated with poor MoAb bioavailability suggest the need for an improved pharmacokinetic behavior of the MoAb to determine its use for prophylaxis of early rejection.

[1]  A. Moreau,et al.  LATE ACUTE FAILURE OF WELL‐HLA-MATCHED RENAL ALLOGRAFTS WITH CAPILLARY CONGESTION AND ARTERIOLAR THROMBI , 1995, Transplantation.

[2]  S. Fournel,et al.  Specific hyporesponsiveness of alloreactive peripheral T cells induced by CD4 antibodies , 1995, European journal of immunology.

[3]  F. Emmrich,et al.  Anti-CD4 monoclonal antibody therapy of late acute rejection in renal allograft recipients--CD4+ T cells play an essential role in the rejection process. , 1995, Transplantation proceedings.

[4]  H Reichenspurner,et al.  Chimeric monoclonal CD4 antibody--a novel immunosuppressant for clinical heart transplantation. , 1994, Transplantation.

[5]  M. Giral,et al.  Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation. A pilot study. , 1994, Transplantation.

[6]  F. Breedveld,et al.  Treatment of Rheumatoid Arthritis with a Chimeric CD4 Monoclonal Antibody (cM‐T412): Immunopharmacological Aspects and Mechanisms of Action , 1994, Scandinavian journal of immunology.

[7]  R. Hershberger,et al.  Use of OKT4A (a murine monoclonal anti-CD4 antibody) in human organ transplantation: initial clinical experience. , 1993, Transplantation proceedings.

[8]  W. Lye,et al.  OKT4A (a murine IgG2a anti-CD4 monoclonal antibody) in human organ transplantation: pharmacokinetics and peripheral pharmacodynamics. , 1993, Transplantation proceedings.

[9]  L. Rumbach,et al.  Use of Monoclonal Antibodies in vivo as a Therapeutic Strategy for Alloimmune or Autoimmune Reactivity: The Besançon Experience , 1992, Immunological reviews.

[10]  J. Madsen,et al.  INDUCTION OF TRANSPLANTATION TOLERANCE IN ADULTS USING DONOR ANTIGEN AND ANTI‐CD4 MONOCLONAL ANTIBODY , 1992, Transplantation.

[11]  E. Field,et al.  Altered IFN-gamma and IL-4 pattern lymphokine secretion in mice partially depleted of CD4 T cells by anti-CD4 monoclonal antibody. , 1992, Journal of immunology.

[12]  P. Morel,et al.  Anti-CD4 monoclonal antibody therapy in severe psoriasis. , 1992, Journal of autoimmunity.

[13]  F. Emmrich,et al.  Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody , 1991, The Lancet.

[14]  J. Scoazec,et al.  In situ immunophenotyping study of endothelial cells of the human hepatic sinusoid: Results and functional implications , 1991, Hepatology.

[15]  T. Sablinski,et al.  CD4 monoclonal antibodies in organ transplantation--a review of progress. , 1991, Transplantation.

[16]  F. Emmrich,et al.  Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody , 1991, The Lancet.

[17]  K. Wood,et al.  CD4: A potential target molecule for immunosuppressive therapy and tolerance induction , 1991 .

[18]  D. Wendling,et al.  Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. , 1991, The Journal of rheumatology.

[19]  F. Emmrich,et al.  Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. , 1991, Arthritis and rheumatism.

[20]  P. Morel,et al.  Anti-CD4 monoclonal antibody administration in renal transplanted patients. , 1990, Clinical immunology and immunopathology.

[21]  R. Colvin,et al.  Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. , 1990, Surgery.

[22]  R. Colvin,et al.  Fc-receptor for mouse IgG1 (Fc gamma RII) and antibody-mediated cell clearance in patients treated with Leu2a antibody. , 1989, Transplantation.

[23]  S. Carding,et al.  MHC control of CD4+ T cell subset activation , 1989, The Journal of experimental medicine.

[24]  S. Cobbold,et al.  Mechanisms of monoclonal antibody‐facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA‐1) molecules in self‐non‐self discrimination , 1988, European journal of immunology.